Ranked by engagement
Top topics — all time page 32
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 32 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Review cadence: how often is a page actually re-checked?
Asking directly, because I could not find a straight answer: Review cadence: how often is a page actually re-checked? Nominating something for promotion into the documentation commons. The topic in question…
|
+20 | 24 | 20k | 15mo |
|
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…
|
4 | 42k | 11mo | |
|
Coming back to: Swirling versus inverting versus leaving it alone
Swirling versus inverting versus leaving it alone Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have seen how quickly…
|
+20 | 24 | 16k | 26d |
|
Why most self-reports here are not experiments, and that is fine
Why most self-reports here are not experiments, and that is fine — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
2 | 46k | 11mo | |
|
Training through a dose escalation week
Training through a dose escalation week — setting out what I have, and where I think it stops being reliable. Maintenance rather than loss, which is the part of this that almost nobody writes about. I have…
|
4 | 42k | 20mo | |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+19 | 23 | 16k | 2d |
|
Getting a referral rather than a refusal
Getting a referral rather than a refusal — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the difference and I would…
|
+8 | 12 | 32k | 2mo |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…
|
+17 | 21 | 17k | 12d |
|
Request: a diff view for wiki revisions
Request: a diff view for wiki revisions — setting out what I have, and where I think it stops being reliable. Nominating something for promotion into the documentation commons. The topic in question keeps…
|
+26 | 30 | 3.1k | 19mo |
|
Whether an aggregate is worth publishing at all: a disputed topic
On the subject in the title: Whether an aggregate is worth publishing at all: a disputed topic Working notes rather than a conclusion. I would like to understand what this number means before I repeat it…
|
+20 | 24 | 18k | 13mo |
|
Conditions that change the calculus rather than forbidding it
Conditions that change the calculus rather than forbidding it Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+28 | 32 | 6.1k | 1d |
|
Follow-up: Reconciling a label claim with a content assay
Reconciling a label claim with a content assay Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it anywhere.…
|
+26 | 30 | 6.5k | 14d |
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…
|
+15 | 19 | 22k | 18mo |
|
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do…
|
+3 | 7 | 33k | 13h |
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
+19 | 23 | 20k | 7mo |
|
A calculator that gives a right answer to the wrong question
Posting this under the heading it deserves: A calculator that gives a right answer to the wrong question Everything below is what sits behind that. I would like to understand what this number means before I…
|
+32 | 36 | 1.9k | 17h |
|
Coming back to: Lurking for two months before posting: was that the right call?
The question in the title: Lurking for two months before posting: was that the right call? I will give what I have already checked below so nobody repeats it. I want to check my reasoning rather than get a…
|
+28 | 32 | 3.3k | 11mo |
|
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
|
+7 | 11 | 31k | 17mo |
|
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with…
|
+32 | 37 | 574 | 5mo |
|
Hello from a laboratory that does not do peptides — does this still hold?
Asking directly, because I could not find a straight answer: Hello from a laboratory that does not do peptides — does this still hold? Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
|
+1 | 5 | 35k | 19mo |
|
Pages past their review date, listed
Pages past their review date, listed Writing it up because I had to work it out twice and would rather nobody else did. Nominating something for promotion into the documentation commons. The topic in question…
|
+26 | 30 | 6.4k | 10mo |
|
Follow-up: I have no scientific background — can I still follow the analytics categories?
Asking directly, because I could not find a straight answer: I have no scientific background — can I still follow the analytics categories? Question in the title. Context below, and I have tried to include…
|
+15 | 19 | 15k | 1mo |
|
Currency conversion and the cost you did not see
Currency conversion and the cost you did not see — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the maintainers asked for.…
|
2 | 44k | 2mo | |
|
About the Resistance training category
Programming while losing weight quickly, realistic expectations, and recovery. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
4 | 40k | 17d | |
|
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than asking about it, in case the…
|
+31 | 35 | 2k | 1d |
|
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
|
2 | 41k | 14mo | |
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
|
+7 | 11 | 26k | 9mo |
|
Revisiting: Body image changing more slowly than the body
Posting this under the heading it deserves: Revisiting: Body image changing more slowly than the body Everything below is what sits behind that. General question, not a request for advice about my own care —…
|
+5 | 9 | 28k | 8h |
|
An orphaned page with no inbound links — the long version
Posting this under the heading it deserves: An orphaned page with no inbound links — the long version Everything below is what sits behind that. Process question about how this site works. I have read the…
|
+14 | 18 | 21k | 10mo |
|
Revisiting: A field-by-field walk through a certificate of analysis
Revisiting: A field-by-field walk through a certificate of analysis Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I…
|
+37 | 41 | 656 | 3mo |